Topic: GW-CAN Givitas Webinar
Description
Who: GW Entrepreneurs, Innovators and Industry Experts
What: A 45-minute webinar to educate the GW CAN entrepreneurial community on Givitas. We will cover the benefits of Givitas and how to sign up and use Givitas.
Time Apr 21, 2021 12:00 PM in Eastern Time (US and Canada)
LUND, Sweden, April 15, 2021 /PRNewswire/ — Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The research collaboration will lead to the expansion of Alligator’s proprietary patient specific immunotherapy Neo-X-Prime™ by incorporating MacroGenics’ proprietary DART® and TRIDENT® multi-specific platforms against two undisclosed targets.
Image: https://biobuzz.io
Margot Connor has over 25 years of experience in diversified Life Science industries bringing executive level expertise to business operations, corporate development and mergers and acquisitions. When Connor took the helm at RoosterBio in 2015, the start-up had only five employees. The company has since grown rapidly to become a leader in the stem cell biomanufacturing industry. It now has about 40 employees in a state-of-the-art facility in Frederick.
Image: https://i95business.com
ROCKVILLE, Md., Apr. 15, 2021 /PRNewswire/ — American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease.
This investment places Gaingels alongside private investors who believe deeply in AGT’s mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.
Image: https://www.americangene.com
Antibodies that target the glycan cap epitope on the ebolavirus glycoprotein (GP) are common in the adaptive response of survivors. A subset is known to be broadly neutralizing, but the details of their epitopes and basis for neutralization are not well understood. Here, we present cryoelectron microscopy (cryo-EM) structures of diverse glycan cap antibodies that variably synergize with GP base-binding antibodies. These structures describe a conserved site of vulnerability that anchors the mucin-like domains (MLDs) to the glycan cap, which we call the MLD anchor and cradle. Antibodies that bind to the MLD cradle share common features, including use of IGHV1-69 and IGHJ6 germline genes, which exploit hydrophobic residues and form β-hairpin structures to mimic the MLD anchor, disrupt MLD attachment, destabilize GP quaternary structure, and block cleavage events required for receptor binding. Our results provide a molecular basis for ebolavirus neutralization by broadly reactive glycan cap antibodies.
Image: https://www.cell.com
We are proud to announce that U.S. News & World Report has designated the Department of Pediatrics at the University of Pennsylvania’s Perelman School of Medicine, located at our hospital, as the number one training program for pediatrics in the country! Please join us in congratulating our faculty, staff and trainees who consistently strive to make our department an exceptional place to work and learn.
Image: https://www.linkedin.com
Dr. James Crowe, Director, Vanderbilt Vaccine Center, is on the forefront of groundbreaking vaccine development.
Studying kidney physiology is essential to increase our understanding and improve the quality of life and prognosis of patients with renal diseases. Organoid cultures have been developed that enable in vitro studies of donor-specific tissue in a controlled three-dimensional (3D) environment. Organoids are 3D multicellular constructs that recapitulate structural and functional characteristics of their organ of origin. Using a modified protocol originally developed for the expansion of adult intestinal Lgr5+ stem cells1, Schutgens et al. recently established kidney tubular epithelial organoids (tubuloids) derived from adult kidney tissue and urine2.
GAITHERSBURG, Md., April 13, 2021 (GLOBE NEWSWIRE) – – Arcellx, a privately held clinical-stage biopharmaceutical company, today announced that it raised $115 million in a Series C financing to advance its pipeline of adaptive and controllable cell therapies. The proceeds will support the company’s development of CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022. In addition, the funding will support initiation of clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from Arcellx’s uniquely controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.
Join us as Alex Hanlon, Ph.D. (Director of the Center for Biostatistics and Health Data Science at Virginia Tech, Professor of Statistics and works closely with researchers on the Health Science and Technology Campus in Roanoke, adjacent to Carilion Clinic and the VTC School of Medicine) and Richard Bendis (Founder, President and CEO of BioHealth Innovation, Inc. and a successful entrepreneur, angel investor, innovation and technology-based economic development leader, international speaker and consultant in the technology and healthcare industries and host of BioTalk) discuss how ‘Big data requires team science.’
